Press Releases
By identifying biomarkers of brain disorders, Cove Neurosciences is working to speed up the development of new treatments. Excerpt from the Press Release: “We know that every patient is different. No two patients with dementia are the same,” says Toronto neurology resident and entrepreneur Nardin Samuel. And yet, she adds, they may end up with…
Read More
Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development Excerpt from the Press Release: SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — Replicate Bioscience, a clinical-stage company pioneering novel self-replicating…
Read More
Excerpt from the Press Release: Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing…
Read More
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement…
Read More
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies Excerpt from the Press Release: SAN DIEGO, Jan. 29, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer…
Read More
Excerpt from the Press Release: MOUNTAIN VIEW, Calif. and OSLO, Norway, Jan. 28, 2025 /PRNewswire/ — Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in…
Read More
January 30, 2025 Alterity Therapeutics – Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – Excerpt…
Read More
BH-30643 is a macrocyclic, mutant selective OMNI-EGFR™ inhibitor with sub-nanomolar potency against classical and atypical EGFR mutations that is maintained even in the presence of T790M +/- C797S resistance mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines…
Read More
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company’s proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential Excerpt from the Press Release: FREMONT, Calif., Jan. 23,…
Read More